Rocket


Overview
Financials
News + Filings
Key Docs
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Inv. presentation
Quarterly results

biote Corp. Create: Alert

All | News | Filings
Date FiledTypeDescription
08/10/2023 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Biote Reports Second Quarter 2023 Financial Results Solid Second Quarter Revenue Growth Continued Progress to Optimize Capital Structure and Enhance Share Liquidity Expansive Strategic Approach Targeting Therapeutic Wellness and Men's Health Categories"
06/08/2023 8-K Entry into a Material Definitive Agreement, Material Modifications to Rights of Security Holders, Submission of Matters to a ...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Amendment No. 1 to Warrant Agreement, by and between the Company and Continental Stock Transfer & Trust Company",
"Biote Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to Warrants IRVING, TX - June 8, 2023 - Biote , a leading solutions provider in preventive healthcare through the delivery of personalized hormone therapy, today announced the expiration and results of its previously announced offer to each holder of its outstanding warrants, each whole warrant exercisable for one share of Class A Common Stock, par value $0.0001 per share , of the Company, at an exercise price of $11.50 per share , the opportunity to receive 0.23 shares of Common Stock in exchange for each Warrant tendered by the holder and exchanged pursuant to the offer , and solicitation of consents from holders of the Warrants to amend the Warrant Agreement, dated as of March 1, 2021 , by and bet..."
06/07/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Underwriting Agreement, by and among the Company, Roth Capital Partners, LLC, as the underwriter, and the Selling Stockholder named therein",
"Underwriting Agreement, by and among the Company, Roth Capital Partners, LLC, as the underwriter, and the Selling Stockholder named therein"
05/19/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
05/09/2023 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Biote Reports First Quarter 2023 Financial Results New Initiative Targets Long-term Growth Opportunity in Men's Health Company Launches Warrant Exchange Offer and Consent Solicitation Maintains 2023 Financial Guidance",
"Biote Announces Commencement of Exchange Offer and Consent Solicitation Relating to Warrants IRVING, TX - May 9, 2023 - Biote , a leading solutions provider in preventive health care through the delivery of personalized hormone therapy, today announced that it has commenced an exchange offer and consent solicitation relating to its 8,397,624 outstanding public warrants to purchase Class A common stock of the Company $0.0001 par value per share , which warrants trade on the Nasdaq Stock Market under the symbol “BTMDW” and 5,106,508 private placement warrants . The purpose of the Offer and Consent Solicitation is to simplify the Company's capital structure and reduce the potential dilutive impact of the warrants. Until the Expiration Date , we are offering to the holders of Warrants the oppo..."
03/28/2023 8-K Quarterly results
03/24/2023 8-K Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review &nbsp...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
02/22/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Amended and Restated Bylaws of biote Corp.",
"Amended and Restated Bylaws of biote Corp."
11/08/2022 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Biote Reports Third Quarter Financial Results Strong Third Quarter Revenue of $42 million Driven by Growth in Procedures 2022 Revenue and Adjusted EBITDA Expected at Upper End of Guidance"
11/07/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Biote Appoints Debby Morris to Board of Directors IRVING, TX - November 7, 2022 - biote Corp. , a leading innovator in preventive health care through the delivery of personalized hormone therapy, today announced the appointment of Debby Morris to Biote's Board of Directors. Ms. Morris brings more than three decades of experience in directing financial operations and strategy to support high-growth companies. Ms. Morris served as the executive vice president and chief financial officer of Apria, Inc. from March 2013 through October 2022. Prior to that, Ms. Morris served as Chief Financial Officer-Americas for Sitel Worldwide Corporation from February 2010 to February 2013. Prior to that she served as a partner of Tatum LLC from 2004 to 2010 and as a director from 2008 to 2010 and provided i..."
10/11/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Biote Releases Updated Corporate Presentation for October 2022 October 10, 2022 IRVING, Texas——Oct. 10, 2022—biote Corp. , a high growth, differentiated medical practice-building business within the hormone optimization space, today released a new Corporate Presentation, which the Company may use from time to time in communications with investors or potential investors. The updated presentation for October can be found under the Investor Relations section of biote's website at https://ir.biote.com/news-events/presentations. About Biote Biote is a woman-led company operating a high growth, differentiated medical practice-building business within the hormone optimization space. Similar to a franchise model, Biote provides the necessary components to enable practitioners to establish, build, ..."
08/25/2022 8-K Quarterly results
08/24/2022 8-K Quarterly results
08/15/2022 8-K/A Quarterly results
08/09/2022 8-K Quarterly results
07/28/2022 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits ...
Docs: "Standby Equity Purchase Agreement, by and between biote Corp. and YA II PN, LTD"
07/19/2022 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT"
07/19/2022 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
06/09/2022 8-K Quarterly results
06/02/2022 8-K Quarterly results
05/26/2022 8-K Quarterly results
05/24/2022 8-K Quarterly results
05/11/2022 8-K Quarterly results
05/04/2022 8-K/A Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Audited Balance Sheet as of March 4, 2021. (as restated)"
03/30/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Analyst Day Presentation",
"Analyst Day Presentation"
03/04/2022 8-K Quarterly results
12/14/2021 8-K/A Quarterly results
12/13/2021 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "Transcript for Webcast"
12/13/2021 8-K Quarterly results
11/18/2021 8-K Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review &nbsp...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
05/17/2021 8-K Quarterly results
04/19/2021 8-K Quarterly results
03/10/2021 8-K Quarterly results
03/05/2021 8-K Quarterly results

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy